• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

验证尼曼-匹克 C 型 5 域临床严重程度量表。

Validation of the 5-domain Niemann-Pick type C Clinical Severity Scale.

机构信息

Mayo Clinic Children's Center, 200 1st St SW, Rochester, MN, 55905, USA.

Clinical Outcomes Solutions, Folkestone, Kent, UK.

出版信息

Orphanet J Rare Dis. 2021 Feb 12;16(1):79. doi: 10.1186/s13023-021-01719-2.

DOI:10.1186/s13023-021-01719-2
PMID:33579322
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7881637/
Abstract

BACKGROUND

Niemann-Pick disease type C (NPC) is an ultra-rare, progressive, genetic disease leading to impaired lysosomal function and neurodegeneration causing serious morbidity and shortened life expectancy. The Niemann-Pick type C Clinical Severity Scale (NPCCSS) is a 17 domain, disease-specific, clinician-reported outcome measure of disease severity and progression. An abbreviated 5-domain NPCCSS scale has been developed (measuring Ambulation, Swallow, Cognition, Speech, and Fine Motor Skills) and the scale reliability has been established. Additional psychometric properties and meaningful change of the scale need, however, to be assessed.

METHODS

Mixed method studies were conducted to ascertain which NPCCSS domains were most important, as well as to explore meaningful change: 1) surveys in caregivers/patients (n = 49) and 2) interviews with clinicians (n = 5) as well as caregivers/patients (n = 28). Clinical trial data (n = 43) assessed construct validity and meaningful change through an anchor-based approach.

RESULTS

Domains identified as most important by clinicians, caregivers, and patients (independent of current age, age of onset, and disease severity) were Ambulation, Swallow, Cognition, Speech, and Fine Motor Skills, indicating content validity of the 5-domain NPCCSS. Criterion validity was shown with the 5-domain NPCCSS being highly correlated with the 17-item NPCCSS total score (excluding hearing domains), r = 0.97. Convergent validity was demonstrated against the 9 Hole Peg Test, r = 0.65 (n = 31 patients), and the Scale for Assessment and Rating of Ataxia (SARA), r = 0.86 (n = 49 patients). Any change was seen as meaningful by patients/caregivers across domains. Meaningful change using trial data and interviews with NPC experts (n = 5) and patients/caregivers (n = 28) suggested that a 1-category change on a domain is equivalent to 1-point change or greater in the 5-domain NPCCSS total score.

CONCLUSIONS

Qualitative and quantitative data support content and construct validity of the 5-domain NPCCSS score as a valid endpoint in NPC trials. A 1-category change on any domain is equivalent to 1-point change or greater in the 5 domain NPCCSS total score, representing a clinically meaningful transition and reflecting loss of complex function and increased disability. Trial registration NCT02612129. Registered 23 November 2015, https://clinicaltrials.gov/ct2/show/NCT02612129.

摘要

背景

尼曼-皮克病 C 型(NPC)是一种罕见的、进行性的遗传疾病,导致溶酶体功能受损和神经退行性变,从而导致严重的发病率和缩短的预期寿命。尼曼-皮克 C 型临床严重程度评分(NPCCSS)是一种 17 个领域的、特定于疾病的、由临床医生报告的疾病严重程度和进展的结果测量工具。已经开发了一个简化的 5 领域 NPCCSS 量表(测量行走、吞咽、认知、言语和精细运动技能),并且已经确定了该量表的可靠性。然而,需要评估该量表的其他心理测量特性和有意义的变化。

方法

采用混合方法研究来确定哪些 NPCCSS 领域最重要,并探讨有意义的变化:1)对护理人员/患者(n=49)进行调查和 2)对临床医生(n=5)以及护理人员/患者(n=28)进行访谈。临床试验数据(n=43)通过基于锚定的方法评估了结构有效性和有意义的变化。

结果

临床医生、护理人员和患者(独立于当前年龄、发病年龄和疾病严重程度)确定的最重要的领域是行走、吞咽、认知、言语和精细运动技能,表明 5 领域 NPCCSS 具有内容有效性。5 领域 NPCCSS 与 17 项 NPCCSS 总分(不包括听力领域)高度相关,r=0.97,表明具有标准有效性。与 9 孔钉测试(r=0.65,n=31 例患者)和共济失调评估和评分量表(SARA)(r=0.86,n=49 例患者)的收敛效度。患者/护理人员在所有领域都认为任何变化都具有意义。使用试验数据和与 NPC 专家(n=5)和患者/护理人员(n=28)的访谈得出的有意义的变化表明,在任何领域中,类别变化相当于 5 领域 NPCCSS 总分中的 1 点或更大变化。

结论

定性和定量数据支持 5 领域 NPCCSS 评分作为 NPC 试验中的有效终点的内容和结构有效性。任何领域的 1 个类别变化相当于 5 领域 NPCCSS 总分中的 1 点或更大变化,代表了临床有意义的转变,反映了复杂功能的丧失和残疾程度的增加。试验注册 NCT02612129。于 2015 年 11 月 23 日注册,https://clinicaltrials.gov/ct2/show/NCT02612129。

相似文献

1
Validation of the 5-domain Niemann-Pick type C Clinical Severity Scale.验证尼曼-匹克 C 型 5 域临床严重程度量表。
Orphanet J Rare Dis. 2021 Feb 12;16(1):79. doi: 10.1186/s13023-021-01719-2.
2
Clinical disease progression and biomarkers in Niemann-Pick disease type C: a prospective cohort study.尼曼-匹克病C型的临床疾病进展与生物标志物:一项前瞻性队列研究。
Orphanet J Rare Dis. 2020 Nov 23;15(1):328. doi: 10.1186/s13023-020-01616-0.
3
International consensus on clinical severity scale use in evaluating Niemann-Pick disease Type C in paediatric and adult patients: results from a Delphi Study.国际共识:临床严重程度量表在评估儿科和成年尼曼-匹克病 C 型患者中的应用:德尔菲研究结果。
Orphanet J Rare Dis. 2021 Nov 18;16(1):482. doi: 10.1186/s13023-021-02115-6.
4
Efficacy and safety of arimoclomol in Niemann-Pick disease type C: Results from a double-blind, randomised, placebo-controlled, multinational phase 2/3 trial of a novel treatment.阿利莫氯胺治疗尼曼-匹克病 C 型的疗效和安全性:一种新型治疗药物的双盲、随机、安慰剂对照、多中心 2/3 期临床试验结果。
J Inherit Metab Dis. 2021 Nov;44(6):1463-1480. doi: 10.1002/jimd.12428. Epub 2021 Sep 7.
5
A master protocol to investigate a novel therapy acetyl-L-leucine for three ultra-rare neurodegenerative diseases: Niemann-Pick type C, the GM2 gangliosidoses, and ataxia telangiectasia.一种用于研究新型治疗药物乙酰-L-亮氨酸的主方案,针对三种超罕见神经退行性疾病:尼曼-匹克 C 型、神经节苷脂贮积症和共济失调毛细血管扩张症。
Trials. 2021 Jan 22;22(1):84. doi: 10.1186/s13063-020-05009-3.
6
Impacts and Burden of Niemann pick Type-C: a patient and caregiver perspective.尼曼匹克 C 型病的影响和负担:患者和照护者的视角。
Orphanet J Rare Dis. 2021 Nov 24;16(1):493. doi: 10.1186/s13023-021-02105-8.
7
Assessment of the reliability, responsiveness, and meaningfulness of the scale for the assessment and rating of ataxia (SARA) for lysosomal storage disorders.评估用于溶酶体贮积症的共济失调评估与分级量表(SARA)的可靠性、反应性和意义。
J Neurol. 2024 Oct;271(10):6888-6902. doi: 10.1007/s00415-024-12664-y. Epub 2024 Sep 3.
8
Long-term administration of intravenous Trappsol® Cyclo™ (HP-β-CD) results in clinical benefits and stabilization or slowing of disease progression in patients with Niemann-Pick disease type C1: Results of an international 48-week Phase I/II trial.长期静脉注射Trappsol® Cyclo™(羟丙基-β-环糊精)可使1型尼曼-匹克病患者获得临床益处,并使疾病进展稳定或减缓:一项为期48周的国际I/II期试验结果
Mol Genet Metab Rep. 2023 Jun 29;36:100988. doi: 10.1016/j.ymgmr.2023.100988. eCollection 2023 Sep.
9
Trial of -Acetyl-l-Leucine in Niemann-Pick Disease Type C.Niemann-Pick 病 C 型中 -乙酰基-l-亮氨酸的试验。
N Engl J Med. 2024 Feb 1;390(5):421-431. doi: 10.1056/NEJMoa2310151.
10
Consistently High Agreement Between Independent Raters of Niemann-Pick Type C1 Clinical Severity Scale in Phase 2/3 Trial.在 2/3 期临床试验中尼曼-匹克 C1 临床严重程度量表的独立评估者之间具有高度一致性。
Pediatr Neurol. 2022 Feb;127:32-38. doi: 10.1016/j.pediatrneurol.2021.11.009. Epub 2021 Nov 29.

引用本文的文献

1
Serum neurofilament light protein as a biomarker in Niemann-Pick disease, type C1.血清神经丝轻链蛋白作为C1型尼曼-匹克病的生物标志物。
Genet Med Open. 2025 Jul 7;3:103443. doi: 10.1016/j.gimo.2025.103443. eCollection 2025.
2
Convergent Validity of the Fine Motor, Speech, and Cognitive Domains of the 5-Domain Niemann-Pick Disease Type C Clinical Severity Scale.5 领域尼曼-皮克病 C 型临床严重程度量表中精细运动、言语和认知领域的收敛效度。
J Child Neurol. 2025 Jun 17:8830738251346348. doi: 10.1177/08830738251346348.
3
Efficacy results from a 12-month double-blind randomized trial of arimoclomol for treatment of Niemann-Pick disease type C (NPC): Presenting a rescored 4-domain NPC Clinical Severity Scale.阿利克仑莫尔治疗C型尼曼-匹克病(NPC)的12个月双盲随机试验的疗效结果:展示重新计分的4领域NPC临床严重程度量表
Mol Genet Metab Rep. 2025 May 28;43:101233. doi: 10.1016/j.ymgmr.2025.101233. eCollection 2025 Jun.
4
Disease-Modifying, Neuroprotective Effect of N-Acetyl-l-Leucine in Adult and Pediatric Patients With Niemann-Pick Disease Type C.N-乙酰-L-亮氨酸对成年和儿童C型尼曼-匹克病患者的疾病修饰性神经保护作用
Neurology. 2025 Jul;105(1):e213589. doi: 10.1212/WNL.0000000000213589. Epub 2025 Jun 13.
5
Clinical, genotypic, and neuropsychological profile in a series of patients with Niemann-Pick type C disease.一系列尼曼-匹克C型病患者的临床、基因型和神经心理学特征
Front Neurol. 2025 Feb 26;16:1542310. doi: 10.3389/fneur.2025.1542310. eCollection 2025.
6
Elevated Cerebrospinal Fluid Total Tau in Niemann-Pick Disease Type C1: Correlation With Clinical Severity and Response to Therapeutic Interventions.1型尼曼-匹克病患者脑脊液总tau蛋白升高:与临床严重程度及治疗干预反应的相关性
J Inherit Metab Dis. 2025 Mar;48(2):e70016. doi: 10.1002/jimd.70016.
7
Characterizing circulating biomarkers for childhood dementia disorders: A scoping review of clinical trials.儿童期痴呆症循环生物标志物的特征分析:一项临床试验的范围综述
Neurotherapeutics. 2025 Mar;22(2):e00546. doi: 10.1016/j.neurot.2025.e00546. Epub 2025 Feb 12.
8
Arimoclomol: First Approval.阿里莫克莫:首次获批。
Drugs. 2025 Jan;85(1):111-116. doi: 10.1007/s40265-024-02129-x. Epub 2024 Dec 24.
9
Cerebrospinal Fluid and Serum Neuron-Specific Enolase in Niemann-Pick Disease Type C1.C1型尼曼-匹克病中的脑脊液和血清神经元特异性烯醇化酶
Am J Med Genet A. 2025 May;197(5):e63970. doi: 10.1002/ajmg.a.63970. Epub 2024 Dec 17.
10
Psychometric evaluation of clinician- and caregiver-reported clinical severity assessments for individuals with CDKL5 deficiency disorder.CDKL5 缺乏症患者的临床医生和照顾者报告的临床严重程度评估的心理测量学评估。
Epilepsia. 2024 Oct;65(10):3064-3075. doi: 10.1111/epi.18094. Epub 2024 Aug 27.

本文引用的文献

1
Clinical disease progression and biomarkers in Niemann-Pick disease type C: a prospective cohort study.尼曼-匹克病C型的临床疾病进展与生物标志物:一项前瞻性队列研究。
Orphanet J Rare Dis. 2020 Nov 23;15(1):328. doi: 10.1186/s13023-020-01616-0.
2
The complexity of a monogenic neurodegenerative disease: More than two decades of therapeutic driven research into Niemann-Pick type C disease.单基因神经退行性疾病的复杂性:尼曼-匹克 C 病治疗驱动研究的 20 多年。
Biochim Biophys Acta Mol Cell Biol Lipids. 2019 Aug;1864(8):1109-1123. doi: 10.1016/j.bbalip.2019.04.002. Epub 2019 Apr 17.
3
Lysosomal storage diseases.溶酶体贮积症。
Nat Rev Dis Primers. 2018 Oct 1;4(1):27. doi: 10.1038/s41572-018-0025-4.
4
Annual severity increment score as a tool for stratifying patients with Niemann-Pick disease type C and for recruitment to clinical trials.年度严重程度递增评分作为一种分层尼曼-匹克病 C 型患者和招募临床试验患者的工具。
Orphanet J Rare Dis. 2018 Aug 16;13(1):143. doi: 10.1186/s13023-018-0880-9.
5
Consensus clinical management guidelines for Niemann-Pick disease type C.尼曼-匹克病 C 型共识临床管理指南。
Orphanet J Rare Dis. 2018 Apr 6;13(1):50. doi: 10.1186/s13023-018-0785-7.
6
Intrathecal 2-hydroxypropyl-β-cyclodextrin decreases neurological disease progression in Niemann-Pick disease, type C1: a non-randomised, open-label, phase 1-2 trial.鞘内注射 2-羟丙基-β-环糊精可降低尼曼-匹克病 C1 型的神经病变进展:一项非随机、开放标签、1-2 期临床试验。
Lancet. 2017 Oct 14;390(10104):1758-1768. doi: 10.1016/S0140-6736(17)31465-4. Epub 2017 Aug 10.
7
Defining natural history: assessment of the ability of college students to aid in characterizing clinical progression of Niemann-Pick disease, type C.定义自然史:评估大学生辅助描述尼曼-匹克病 C 型临床进展的能力。
PLoS One. 2011;6(10):e23666. doi: 10.1371/journal.pone.0023666. Epub 2011 Oct 3.
8
Niemann-Pick disease type C.尼曼-匹克病 C 型。
Orphanet J Rare Dis. 2010 Jun 3;5:16. doi: 10.1186/1750-1172-5-16.
9
Lipids on trial: the search for the offending metabolite in Niemann-Pick type C disease.脂质受审:在尼曼-匹克 C 型疾病中寻找罪魁祸首代谢物。
Traffic. 2010 Apr;11(4):419-28. doi: 10.1111/j.1600-0854.2010.01032.x. Epub 2010 Jan 6.
10
Clinical experience with miglustat therapy in pediatric patients with Niemann-Pick disease type C: a case series.尼曼-匹克病 C 型患儿米格列奈酯治疗的临床经验:病例系列研究。
Mol Genet Metab. 2010 Apr;99(4):358-66. doi: 10.1016/j.ymgme.2009.11.007. Epub 2009 Nov 29.